BD Highlights the Latest Innovations in Drug Delivery at Pharmapack 2025

FRANKLIN LAKES, N.J. (January 20, 2025) - BD (Becton, Dickinson and Company), a leading global medical technology company, will showcase a wide range of cutting-edge drug delivery innovations at Pharmapack, Europe's leading drug delivery event from January 22-23, 2025, at Paris Expo, Porte de Versailles, in Paris.

"With a focus on biologics, including GLP-1s, vaccines, and acute care, BD continues to innovate across therapeutic areas while partnering with pharmaceutical and biotech companies to address the growing trend toward patient self-care and home-based treatment," said Fernand Goldblat, VP/GM BD Medical-Pharmaceutical Systems, Prefillable Syringes Platform. "Our presence at Pharmapack reflects our commitment to advancing therapeutic outcomes, simplifying drug delivery systems, and empowering patients around the world."

This year's showcase at booth E55 will feature an array of innovative products designed to meet the growing demands of pharmaceutical and biotech industries across a range of therapeutic areas. As a Premium Partner at Pharmapack, BD will participate in multiple educational sessions to share insights that build on decades of expertise in drug delivery excellence.

At the event, BD will host two, in-person learning labs:

• "Derisking Drug-Device ANDA Submissions: A Case Study Using Comparative Analysis and Human Factors Data" on January 22, from 15:50 - 16:20 presented by Laurie Brunet-Manquat, Medical, Clinical and Human Factors Specialist.
• "Straight to the point: how needle choice can enhance subcutaneous delivery of biologics and patient self-injection experience" on January 23, from 10:50 - 11:20 presented by Claire Lageat, Clinical and Human Factors Specialist.

BD is also sponsoring a conference on Large Volume Drug Delivery on January 22, starting at 14:10. At 15:15, Peter Skutnik, Business Director, Wearables from BD will present "Navigating through the challenges and opportunities with expanding design space requirements for complex biologics formulations". There will also be a panel discussion that will bring together industry experts to discuss proactive supplier collaboration across the pharma ecosystem for combination product success from 16:05 - 17:00. Beth DiLauri, Director of Portfolio Marketing from BD will participate in the panel discussion.

Featured products include:

• BD iDFill™ Individual Prefillable Syringe Identification*: A Radio Frequency Identification (RFID) based solution for prefillable syringes (PFS) which aims to enhance efficiency and improve traceability during fill-and-finish operations. Visit the BD booth for a live demo to see how it works.
• BD Neopak™ XtraFlow™ Glass Prefillable Syringe: Designed for subcutaneous delivery of high-viscosity biologics with a shorter 8mm needle length and thinner wall technology. BD's product demonstration booth will offer attendees an interactive experience, showcasing how BD Neopak™ XtraFlow™ Glass Prefillable Syringe is allowing drug developers to Flow Beyond Limits.
• BD SCF™ PremiumCoat® 1-3mL Plunger Stopper: Engineered to support the subcutaneous injection of complex biologics and viscous solutions through reduced** glide force and glide force variability¹, and guarantee of no ribs not touching to support container closure integrity².

Additionally, BD will feature BD Accuspray™ Nasal Spray System, a disposable system for nasal administration of vaccines, BD Effivax™ Glass Prefillable Syringe, BD Hylok™ Glass Prefillable Syringe for intravenous drugs and hyaluronic acid, BD Libertas™ Wearable Injector*** and BD Evolve™ On-body Injector**** wearable solutions, as well as BD Physioject™ Disposable Autoinjector and BD Vystra™ Disposable Pen for biologics.

BD is actively investing in advancing technology and optimizing manufacturing to further enhance capabilities and deliver patient centered delivery systems. BD is committed to driving innovation for combination products across the design space and the company looks forward to continued collaboration with biopharmaceutical partners.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.

* BD iDFill™ is in development, and accordingly some statements are forward-looking and subject to various risks and uncertainties. Any actual solution placed on the market may differ.

** When compared to the BD SCF™ FluroTec® Plunger Stopper. Results are based on a sample of 100 pieces of BD Flurotec® and BD SCF™ PremiumCoat®. Variables compared were Mean (glide force reduction) and standard deviation (glide force variability).

¹TR20234488 Le Pont-de-Claix, France; Becton, Dickinson and Company; 2024.

²BD SCF™ PremiumCoat® Plunger Stopper 1-3mL Customer quality specifications. Le Pont-de-Claix, France; Becton, Dickinson and Company; 2023.

***BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.

****BD Evolve™ On-body Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Evolve™ On-body Injector is a device component intended for drug-device combination products and subject to EU CE mark certification but not FDA 510(k) clearance.

PremiumCoat is a registered trademark of AptarGroup, Inc.

FluroTec is a registered trademark of West Pharmaceutical Services, Inc.

Public link

Please use the above public link if you want to share this noodl on another website.